Vigene Bioscience offered complimentary monthly scientific webinars on GMP productions of viral vectors and plasmids. Please join us and interact with our scientists. Below is the webinar information:
Upcoming Webinar – Plasmid Production, Engineering and Process Considerations
May 7, 2021 12:00 PM – 1:00 PM EDT
Speaker – Dr. Ruofang Wang and Chris Porzondek
GMP-Ready or full GMP grade plasmid DNA can either be used as gene therapy itself or as critical material for viral vector production. What grade of plasmid is right for your process? What are the different steps involved in Research, GMP-Ready, or GMP plasmid production and how do these steps affect what is needed from a regulatory process or documentation standpoint? What timelines can be expected from different grades of material?
On Demand Webinar – Standardized AAV Viral Vector and Plasmid Manufacturing and Analytics
Speaker – Dr. Jeffrey Hung
Scalability and affordability are two of the main prominent challenges for the AAV gene therapy supply. To meet the need for increased viral vector manufacturing, we propose to establish standardized AAV viral vector and plasmid manufacturing and analytics to ensure consistency of the productivity and to accelerate the release of GMP materials. Transfection efficiency, selection of producer cells, upstream production and downstream purification by chromatography as well as packaging plasmid manufacturing will be discussed. In addition, the newly launched AAV reference standards for AAV testing and analytics and their application for the standardized AAV testing will be overviewed.
On Demand Webinar – Design, manufacturing and analytics of new AAV Reference Materials – a Case Study
Speaker – Dr. Jeffrey Hung
Reference materials for gene therapy has been lacking, resulting in poor inter-lab and inter-product comparability. Vigene has developed a standardized production protocol and analytics panel for AAV1, AA2, AAV5, AAV6, AAV8 and AAV9 empty and full capsids to facilitate the testing of AAV gene therapy products. The production process and analytical results will be discussed. Vigene’s Chief Commercial Officer, Dr. Jeff Hung, will also share some lesson learned from this year-long endeavor.
On Demand Webinar – COVID-19 Vaccine Research Tools Using Non-Integrating Lentivirus and AAV and Adenoviral Vectors
Speaker – Dr. Mingjuan Liu
Are you looking for effective research reagents to serve as vaccine positive controls, to generate SARS-CoV-2 antibodies, or to screen the neutralizing antibodies? If so, look no further. Vigene Biosciences engineered SARS-CoV-2 vaccine research tools in adenoviral vector, AAV vector and pseudotyped lentivirus vector to facilitate the research on SARS-CoV-2. All 3 types of viral vector-delivered S protein can generate sufficient amount of antibody in mouse models. These research reagents are very useful in serving as positive controls for antibody response to SARS-CoV-2 and SARS-CoV-2 antibody generation.
On Demand Webinar – Viruses Friends or Foes? An Overview of Viruses, Virus Therapies and Viral Vectors
Speaker – Dr. Jeffrey Hung
Human’s genome and history have been scattered with different kinds of viruses, which are the unique microbial organisms that lack the capacity to propagate and reproduce outside of a host cell. Viruses including SARS-COV2, appear to be foes of mankind in that they cause diseases even death. However, thanks to the great efforts of many biomedical researchers, viruses have also been tamed to bring healthy genes into cells and humans to cure diseases such as cancer and genetic disorders. On this aspect, recombinant viruses are definitely our great friends. DNA and RNA Viruses, the epidemiology of virus diseases, virus therapies and the engineering and manufacturing of viral vector will be discussed.
On Demand Webinar – Scalable GMP Production of AAV, Lentivirus & Plasmid
Speaker: Dr. Jeffrey Hung
AAV and lentivirus are commonly used viral vectors in gene and cell therapies to deliver therapeutic genes into patients. There are many challenges in scaling up to GMP production of viral vectors, including choosing the right producer cell line and robust process development optimization to achieve consistent yields. Learn more about the factors that affect successful scale up for GMP production of AAV, lentivirus and plasmids.
On Demand Webinar – Lentivirus Production Optimization
Speaker – Dr. James Cody
Lentiviral vectors are widely used in gene and cell therapy. Key questions to be answered include: What are the considerations in scaling up to GMP production? What is the lentivirus GMP production process? What release tests must be completed before the lentivirus vectors can be used in patients?
On Demand Webinar – GMP Plasmid Production and Analytical Testing
Speaker – Dr. Guoan Wang
GMP-Ready or full GMP grade plasmid DNA can either be used as gene therapy itself or as critical material for viral vector production. The large scale GMP plasmid production needs to address multiple challenges. Key questions to be answered include: What steps are involved in the GMP production process of plasmids? How are the different grades of plasmids are manufactured and what are their differences? What release tests are required for GMP plasmids release tests?